• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy?

作者信息

Wang Luxiang, Zhang Chunli, Fan Shuang, Mo Xiaodong, Hu Xiaoxia

机构信息

Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai 200025, China.

Collaborative Innovation Center of Hematology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.

出版信息

Innovation (Camb). 2023 Jun 20;4(4):100461. doi: 10.1016/j.xinn.2023.100461. eCollection 2023 Jul 10.

DOI:10.1016/j.xinn.2023.100461
PMID:37448742
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10336665/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df59/10336665/caaf4eed3eea/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df59/10336665/caaf4eed3eea/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df59/10336665/caaf4eed3eea/gr1.jpg

相似文献

1
Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy?完全缓解（CR1）的成年中危急性髓系白血病（AML）患者的治疗选择：异基因造血干细胞移植（Allo-HSCT）还是化疗？
Innovation (Camb). 2023 Jun 20;4(4):100461. doi: 10.1016/j.xinn.2023.100461. eCollection 2023 Jul 10.
2
Effects of post-remission chemotherapy before allo-HSCT for acute myeloid leukemia during first complete remission: a meta-analysis.缓解后化疗对首次完全缓解期急性髓系白血病患者allo-HSCT 前的影响：一项荟萃分析。
Ann Hematol. 2018 Sep;97(9):1519-1526. doi: 10.1007/s00277-018-3414-6. Epub 2018 Jun 26.
3
Efficacy of myeloablative allogeneic hematopoietic stem cell transplantation in adult patients with MLL-ELL-positive acute myeloid leukemia.清髓性异基因造血干细胞移植治疗MLL-ELL阳性成年急性髓系白血病患者的疗效
Int J Hematol. 2015 Jul;102(1):86-92. doi: 10.1007/s12185-015-1779-z. Epub 2015 Mar 11.
4
Acute myeloid leukemia patient with and double mutation should undergo allogeneic hematopoietic stem cell transplantation in CR1 for better prognosis.伴有 和 双突变的急性髓系白血病患者应在完全缓解期1（CR1）接受异基因造血干细胞移植，以获得更好的预后。 （注：原文中“and double mutation”处有信息缺失）
Cancer Manag Res. 2019 May 8;11:4129-4142. doi: 10.2147/CMAR.S194523. eCollection 2019.
5
Assessing the efficacy of allogeneic hematopoietic stem cells transplantation (allo-HSCT) by analyzing survival end points in defined groups of acute myeloid leukemia patients: a retrospective, multicenter Polish Adult Leukemia Group study.评估异基因造血干细胞移植（allo-HSCT）的疗效，通过分析特定组别急性髓细胞白血病患者的生存终点：一项回顾性、多中心波兰成人白血病组研究。
Am J Hematol. 2015 Oct;90(10):904-9. doi: 10.1002/ajh.24113.
6
Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.中剂量阿糖胞苷诱导化疗和随后异基因造血干细胞移植对高危急性髓系白血病结局的影响。
J Cancer Res Clin Oncol. 2022 Jun;148(6):1481-1492. doi: 10.1007/s00432-021-03733-0. Epub 2021 Jul 23.
7
The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.无 FLT3-ITD、NPM1 和双等位 CEBPA 突变的中危急性髓系白血病微小残留病检测对预后和缓解后治疗选择的影响。
Hematology. 2021 Dec;26(1):179-185. doi: 10.1080/16078454.2021.1880753.
8
Efficacy of allogeneic and autologous hematopoietic SCT in patients with AML after first complete remission.异体和自体造血干细胞移植在首次完全缓解后 AML 患者中的疗效。
Bone Marrow Transplant. 2013 Mar;48(3):383-9. doi: 10.1038/bmt.2012.154. Epub 2012 Sep 24.
9
Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission.清髓性单倍体相合移植优于中危急性髓细胞白血病患者首次完全缓解后的化疗。
Clin Cancer Res. 2019 Mar 15;25(6):1737-1748. doi: 10.1158/1078-0432.CCR-18-1637. Epub 2018 Nov 26.
10
Risk factors for post-transplant relapse and survival in younger adult patients with t(8;21)(q22;q22) acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: A multicenter retrospective study.接受异基因造血干细胞移植的t(8;21)(q22;q22)急性髓系白血病年轻成年患者移植后复发和生存的危险因素：一项多中心回顾性研究。
Front Oncol. 2023 Feb 9;13:1138853. doi: 10.3389/fonc.2023.1138853. eCollection 2023.

引用本文的文献

1
Artificial intelligence-based predictive model for relapse in acute myeloid leukemia patients following haploidentical hematopoietic cell transplantation.基于人工智能的单倍体造血细胞移植后急性髓系白血病患者复发预测模型。
J Transl Int Med. 2025 Jun 20;13(3):253-266. doi: 10.1515/jtim-2025-0028. eCollection 2025 Jun.
2
monitoring before and after allogeneic haematopoietic stem cell transplantation for acute myeloid leukemia: A report from the TROPHY study group.急性髓系白血病异基因造血干细胞移植前后的监测：TROPHY研究组报告
J Transl Int Med. 2025 Jul 31;13(4):375-385. doi: 10.1515/jtim-2025-0032. eCollection 2025 Aug.
3

本文引用的文献

1
DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant.DNA 测序检测造血细胞移植前急性髓系白血病成人患者的残留疾病。
JAMA. 2023 Mar 7;329(9):745-755. doi: 10.1001/jama.2023.1363.
2
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.异基因造血细胞移植与标准强化化疗治疗中危急性髓系白血病患者的随机临床试验。
JAMA Oncol. 2023 Apr 1;9(4):519-526. doi: 10.1001/jamaoncol.2022.7605.
3
Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission.
Venetoclax and azacitidine compared with intensive chemotherapy for adverse-risk acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation in first complete remission: A multicenter study of TROPHY group.
维奈托克与阿扎胞苷对比强化化疗用于首次完全缓解后接受异基因造血干细胞移植的高危急性髓系白血病患者：TROPHY组的多中心研究
Chin J Cancer Res. 2025 Jun 30;37(3):417-431. doi: 10.21147/j.issn.1000-9604.2025.03.10.
4
Comparison of plasma sterilizer and conventional laminar flow room in allogeneic hematopoietic stem cell transplant recipients.异基因造血干细胞移植受者中血浆灭菌器与传统层流室的比较。
Cell Transplant. 2025 Jan-Dec;34:9636897251335722. doi: 10.1177/09636897251335722. Epub 2025 Apr 30.
5
Humanized anti-CD25 monoclonal antibody replaces methotrexate as acute graft-versus-host disease prophylaxis in haploidentical allogeneic haematopoietic stem cell transplantation.人源化抗CD25单克隆抗体在单倍体相合异基因造血干细胞移植中替代甲氨蝶呤用于预防急性移植物抗宿主病。
Br J Haematol. 2025 Feb;206(2):615-627. doi: 10.1111/bjh.19958. Epub 2024 Dec 22.
6
Allogeneic hematopoietic stem cell transplantation could overcome the poor prognosis of DNMT3ANPM1FLT3-ITD in acute myeloid leukemia: real-world multicenter analysis in China.异基因造血干细胞移植可改善急性髓系白血病中DNMT3A、NPM1、FLT3-ITD突变患者的不良预后：中国真实世界多中心分析
Front Med. 2025 Feb;19(1):90-100. doi: 10.1007/s11684-024-1091-5. Epub 2024 Dec 7.
7
Optimization of T-cell-replete haploidentical hematopoietic stem cell transplantation: the Chinese experience.T细胞充足的单倍体相合造血干细胞移植的优化：中国经验
Haematologica. 2025 Mar 1;110(3):562-575. doi: 10.3324/haematol.2024.286194.
8
Quality-adjusted time without symptoms or toxicity analysis of haploidentical-related donor identical sibling donor hematopoietic stem cell transplantation in acute myeloid leukemia.单倍体相合相关供者与同基因同胞供者造血干细胞移植治疗急性髓系白血病的无症状或毒性的质量调整时间分析
Chin J Cancer Res. 2024 Oct 30;36(5):530-544. doi: 10.21147/j.issn.1000-9604.2024.05.06.
9
Pre-transplantation levels of lysine (K)-specific methyltransferase 2A () partial tandem duplications can predict relapse of acute myeloid leukemia patients following haploidentical donor hematopoietic stem cell transplantation.移植前赖氨酸（K）特异性甲基转移酶2A（）部分串联重复水平可预测单倍体相合供者造血干细胞移植后急性髓系白血病患者的复发情况。
Blood Sci. 2024 Sep 25;6(4):e00207. doi: 10.1097/BS9.0000000000000207. eCollection 2024 Oct.
10
Single-cell immune landscape of measurable residual disease in acute myeloid leukemia.急性髓系白血病中可测量残留病的单细胞免疫景观。
Sci China Life Sci. 2024 Nov;67(11):2309-2322. doi: 10.1007/s11427-024-2666-8. Epub 2024 Jul 19.
在首次缓解期和第二次缓解期接受异基因干细胞移植的 AML 患者中，MRD 状态的影响。
Blood Adv. 2022 Aug 9;6(15):4570-4580. doi: 10.1182/bloodadvances.2022007168.
4
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia.GIMEMA AML1310 试验：针对新诊断的急性髓系白血病的年轻成年人，采用风险适应、MRD 导向的治疗。
Blood. 2019 Sep 19;134(12):935-945. doi: 10.1182/blood.2018886960. Epub 2019 Aug 8.
5
Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission.清髓性单倍体相合移植优于中危急性髓细胞白血病患者首次完全缓解后的化疗。
Clin Cancer Res. 2019 Mar 15;25(6):1737-1748. doi: 10.1158/1078-0432.CCR-18-1637. Epub 2018 Nov 26.